Rutinib Cream

Product Details

Rutinib Cream – Effective Relief for Psoriasis and Eczema

Rutinib Cream also known as OPZELURA contains Ruxolitinib, a Janus kinase (JAK) inhibitor used for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis (eczema). Ruxolitinib works by blocking specific enzymes involved in the inflammatory process, helping to reduce redness, itching, and swelling, thereby improving skin health.

Uses

• Atopic Dermatitis (Eczema): Provides relief from inflammation, itching, and redness.
• Vitiligo: Helps restore skin pigmentation in certain cases.
• Psoriasis: Manages symptoms such as scaling, redness, and discomfort.
• Other Skin Disorders: May be used under medical guidance for other inflammatory skin conditions.

How Rutinib Cream Works

Ruxolitinib inhibits Janus kinase (JAK) enzymes that regulate immune responses and inflammation. By blocking JAK pathways, the cream reduces excessive immune activity, alleviating symptoms of inflammation and restoring skin integrity.

Common Side Effects

• Mild irritation or redness at the application site
• Burning or stinging sensation
• Temporary skin dryness

Serious Side Effects (Seek Immediate Medical Attention)

• Severe skin irritation or allergic reactions
• Signs of infection (e.g., redness, swelling, warmth)
• Discoloration or changes in skin texture

Key Features

• Contains Ruxolitinib, a potent JAK inhibitor for topical use.
• Reduces inflammation and relieves symptoms of eczema and psoriasis.
• Proven efficacy in restoring skin pigmentation in vitiligo.
• Easy-to-apply cream for targeted relief.

Precautions

• Avoid Use on Broken Skin: Do not apply to open wounds or damaged areas.
• Pregnancy and Breastfeeding: Consult your healthcare provider before use.
• Use as Directed: Follow your doctor’s instructions regarding application frequency and duration.
• Sun Protection: Protect treated areas from sun exposure to prevent photosensitivity.

References:

• Mayo Clinic, “Ruxolitinib Topical: Atopic Dermatitis and Vitiligo,” [Accessed on DATE], https://www.webmd.com/drugs/2/drug-182367/opzelura-topical/details
• U.S. Food and Drug Administration, “Opzelura (Ruxolitinib) Cream for Vitiligo and Eczema Treatment,” https://pmc.ncbi.nlm.nih.gov/articles/PMC10036407/